We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, …
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$339M
▼ -65.9% YoY
Op. Margin
–
ROIC
-30.06%
▲ +22.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$305M
▼ -89.1% YoY
Op. Cash Flow (TTM)
-$305M
▼ -89.0% YoY
Net Debt
-$757M
Net Cash Position
Cash & Equiv.
$759M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with PRAX
Held by ETFs
PRAX is in 82 US ETFs. The largest of them, with PRAX's weight in each:
Praxis Precision Medicines (PRAX) in three numbers
Questions about Praxis Precision Medicines
Is Praxis Precision Medicines a high-quality business?
Praxis Precision Medicines scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$757M, and its weakest is return on capital at -30.1%. The Quality tab shows every check against its target.
Does Praxis Precision Medicines (PRAX) pay a dividend?
No. Praxis Precision Medicines (PRAX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 31 Jul 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in PRAX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing PRAX
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.